Pembrolizumab

Red

Brand Name(s):KEYTRUDA

Indication:All licensed indications

Rationale:1,2,3

Considered:Aug-15

Review Date:Jan-26

Comments:
NICE TA661 Recommends pembrolizumab for untreated metastatitic/unresectable recurrent head and neck squamous cell carcinoma in adults with PD-L1+ve tumours.
NICE TA650 does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma in adults. Drug Safety Update
Reports of organ transplant rejection
Jul-17
…………………………
NICE TA428
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
January 2017